ClinicalTrials.gg

Program

TQA3605

A development code. Also written as “TQA3605 tablets”, “TQA3605 tablets plus NAs” and “TQA3605 Tablets”.

In Sino Biopharmaceutical's pipeline, HBV衣壳蛋白抑制剂 (CAM). Its studies are mostly in Hepatitis B, Chronic, led by Sino Biopharmaceutical.

Furthest: phase 3, since Aug 28, 20264 company-led studies, 2 open or runningNext primary completion: Sep 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sino Biopharmaceutical42 open or runningphase 3since Aug 28, 2026Nov 20, 2023Sep 2028phase 3 · NCT07797231
  • Named in Sino Biopharmaceutical’s own pipeline as TQA3605, phase 2, as of Nov 16, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 20, 2023First study: phase 2 study in Hepatitis B, ChronicFirst studyNCT06150014 · 88 enrolled · China
  2. Oct 14, 2024Phase 2 study in HBV Infection With LLVNCT06644417 · 122 enrolled · China
  3. May 18, 2025Phase 2 study in Hepatitis B, ChronicNCT06990776 · China
  4. Aug 28, 2026Phase 3 study in Hepatitis B, ChronicPhase 3 reachedNCT07797231 · 930 planned · China

Ahead

  1. Sep 2028Primary completion: phase 3 study in Hepatitis B, ChronicNCT07797231

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“HBV衣壳蛋白抑制剂 (CAM)”the company's pipeline, read by Claude · source

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07797231Hepatitis B, Chronic · China3Not yet recruitingSep 2028930
NCT06990776Hepatitis B, Chronic · China2WithdrawnJul 17, 20250
NCT06644417HBV Infection With LLV · China2CompletedAug 25, 2025122
NCT06150014Hepatitis B, Chronic · China2Active, not recruitingDec 202588

How it is read

Names in the registry

  • “TQA3605 tablets”, 2 entries
  • “TQA3605 tablets plus NAs”, 1 entry
  • “TQA3605 Tablets”, 1 entry

Codes read as this program: TQA3605.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.